On 27 February 2023, the YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Shenzhen HEC Industrial entered into a framework agreement in relation to the provision of production and testing services, which includes inspection and testing, production and other services by the Company to Shenzhen HEC Industrial (the ``Entrusted Production and Inspection Services Framework Agreement''). The principal terms of the Entrusted Production and Inspection Services Framework Agreement are as follows: Date 27 February 2023 Parties the Company (for itself and on behalf of its subsidiaries); and Shenzhen HEC Industrial (for itself and on behalf of its subsidiaries) Term From 27 February 2023 to 31 December 2025 Nature of transaction The Company agreed to provide Production and Inspection Services to Shenzhen HEC Industrial. The scope of the entrusted Production and Inspection Services includes provision of production, inspection and testing services to Dong An Tai, Dong An Qiang, Dong An Rui, Dong Tong Shen, other generic drugs, other new drugs, insulin degludec/insulin aspart, insulin degludec/liraglutide injection and intermediates of generic drugs (``Production and Inspection Services'').

Payment method Shenzhen HEC Industrial will pay the corresponding amount to the Company (via telegraphic transfer) within 90 days upon receipt of the invoice issued by the Company. Conditions Precedent The Entrusted Production and Inspection Services Framework Agreement is conditional upon the satisfaction of the following conditions precedent: (i) the due execution of the Entrusted Production and Inspection Services Framework Agreement by both parties; and (ii) having obtained approval from the Independent Shareholders at the EGM in relation to the Entrusted Production and Inspection Services Framework Agreement and the transactions contemplated thereunder and the proposed annual caps by the Company in accordance with the Listing Rules. On 27 February 2023, the Company and Shenzhen HEC Industrial entered into a framework agreement in relation to the sale of specific pharmaceutical production and inspection equipment (including Glatter fluidized bed), quality inspection equipment and other equipment (the ``Equipment Sales Framework Agreement'') by the Company to Shenzhen HEC Industrial.

The principal terms of the Equipment Sales Framework Agreement are as follows: Date 27 February 2023 Parties the Company (for itself and on behalf of its subsidiaries); and Shenzhen HEC Industrial (for itself and on behalf of its subsidiaries) Term From 27 February 2023 to 31 December 2023 Nature of transaction The Company agreed to sell specific pharmaceutical production equipment (including Glatter fluidized bed), quality inspection equipment and other equipment (the ``Equipment'') to Shenzhen HEC Industrial. Payment method Shenzhen HEC Industrial will pay the corresponding amount to the Company (via telegraphic transfer) within 90 days upon receipt of the invoice issued by the Company. Conditions precedent The Equipment Sales Framework Agreement is conditional upon the satisfaction of the following conditions precedent: (i) the due execution of the Equipment Sales Framework Agreement by both parties; and (ii) having obtained approval from the Independent Shareholders at the EGM in relation to the Equipment Sales Framework Agreement and the transactions contemplated thereunder and the proposed annual cap by the Company in accordance with the Listing Rules.